Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity-Reference-Cited by-同舟云学术

Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity

Published:2017-09 Issue:3 Volume:124 Page:386-394
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

De-Colle Chiara,Yaromina Ala,Hennenlotter Joerg,Thames Howard,Mueller Arndt-Christian,Neumann Tim,Stenzl Arnulf,Scharpf Marcus,Fend Falko,Ricardi Umberto,Baumann Michael,Zips Daniel,Menegakis Apostolos

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference63 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J Clin,2012

3. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA,1998

4. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy;Kupelian;J Clin Oncol,2002

5. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes;Cahlon;Int J Radiat Oncol Biol Phys,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer;Cancers;2024-02-26

2. Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease;Molecular Oncology;2023-03-16

3. Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome;Theranostics;2023

4. Predicting tumour radiosensitivity to deliver precision radiotherapy;Nature Reviews Clinical Oncology;2022-12-07

5. Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters;Radiation Oncology;2022-10-05